First Ever Parkinson’s Disease Vaccine Shows Promise

The first ever clinical trial of a Parkinson’s disease (PD) vaccine is achieving promising results. AFFiRiS AG, a Vienna-based biotechnology company developing peptide-based vaccines, reported results of a phase I clinical trial of their proprietary anti alpha-synuclein therapy, called PD01A, in PD patients. Alpha-synuclein protein aggregates are a hallmark of PD pathology, and researchers have hypothesized the reducing protein accumulation would be an effective therapeutic strategy for PD. In this trial, funded by the Michael J. Fox Foundation (MJFF), two doses of the therapeutic vaccine were shown to be safe and well-tolerated, meeting the primary endpoint of the trial. Moreover, the vaccine-treated patients showed a trend toward functional stabilization. The next study planned is a follow-up to assess clinical and immunological effects of a booster vaccine, which is expected to begin recruiting in September 2014.

The first ever clinical trial of a Parkinson’s disease (PD) vaccine is achieving promising results. AFFiRiS AG, a Vienna-based biotechnology company developing peptide-based vaccines, reported results of a phase I clinical trial of their proprietary anti alpha-synuclein therapy, called PD01A, in PD patients. Alpha-synuclein protein aggregates are a hallmark of PD pathology, and researchers have hypothesized the reducing protein accumulation would be an effective therapeutic strategy for PD. In this trial, funded by the Michael J. Fox Foundation (MJFF), two doses of the therapeutic vaccine were shown to be safe and well-tolerated, meeting the primary endpoint of the trial. Moreover, the vaccine-treated patients showed a trend toward functional stabilization. The next study planned is a follow-up to assess clinical and immunological effects of a booster vaccine, which is expected to begin recruiting in September 2014.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail